Metabolic disturbances and renal stone promotion on treatment with topiramate: a systematic review
- 22 May 2014
- journal article
- review article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 77 (6) , 958-964
Abstract
The use of topiramate, which is prescribed for the management of epilepsy, for migraine headache prophylaxis and as a weight-loss agent, has been associated with the development of metabolic acidosis, hypokalaemia and renal stone disease. We systematically reviewed all the literature. The systematic review of the literature was realized using the principles underlying the UK Economic and Social Research Council guidance on the conduct of narrative synthesis and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement. Fourty-seven reports published between 1996 and 2013 were retained for the final analysis. Five case-control studies and six longitudinal studies addressed the effect of topiramate on acid-base and potassium balance. A significant tendency towards mild-to-moderate hyperchloraemic metabolic acidosis (with bicarbonate ≤21.0 mmol l(-1) in approximately every third case) and mild hypokalaemia (with potassium ≤3.5 mmol l(-1) in 10% of the cases) was noted on treatment with topiramate, which was similar in children and adults. A single study observed that topiramate causes mild hyperuricaemia in male adults. A tendency towards hypocitraturia, a recognized promoter of renal stone formation, was noted in all patients on topiramate. Increasing evidence supports the use of topiramate. Topiramate is generally well tolerated, and serious adverse events are rare. Nonetheless, the present systematic review of the literature indicates that its use is linked with the development of acidosis, hypokalaemia, hyperuricaemia and hypocitraturia.Keywords
This publication has 57 references indexed in Scilit:
- Guide to Receptors and Channels (GRAC), 5th editionBritish Journal of Pharmacology, 2011
- Effect of topiramate on acid–base balance: extent, mechanism and effectsBritish Journal of Clinical Pharmacology, 2009
- Serum Uric Acid and Lipid Levels While Taking Topiramate for MigraineHeadache: The Journal of Head and Face Pain, 2008
- Intraoperative Metabolic Acidosis Induced by Chronic Topiramate Intake in Neurosurgical PatientsJournal of Neurosurgical Anesthesiology, 2008
- Migraine and Topiramate Induced DyspneaHeadache: The Journal of Head and Face Pain, 2007
- Increased propensity for calcium phosphate kidney stones with topiramate useExpert Opinion on Drug Safety, 2007
- Topiramate monotherapy in epilepsy and migrainepreventionClinical Therapeutics, 2005
- Topiramate and metabolic acidosis: a case series and review of the literaturePediatric Anesthesia, 2005
- Topiramate in the Long‐Term Management of Refractory EpilepsyEpilepsia, 2000
- Efficacy and safety of topiramate in refractory epilepsy: a long-term prospective trialThe Italian Journal of Neurological Sciences, 1996